Chemical formula: C₂₂H₃₁N₃O₅ Molecular mass: 417.499 g/mol PubChem compound: 56330
Cilazapril is a specific, long-acting angiotensin-converting enzyme (ACE) inhibitor which suppresses the renin-angiotensin-aldosterone system and thereby the conversion of the inactive angiotensin I to angiotensin II, which is a potent vasoconstrictor.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C09AA08 | Cilazapril | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VASCACE Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| INHIBACE Tablet | Health Products and Food Branch (CA) | MPI, CA: SPM |
Cilazapril is an active ingredient of these brands:
Austria (AT)
Brazil (BR)
Canada (CA)
Germany (DE)
Israel (IL)
New Zealand (NZ)
Poland (PL)South Africa (ZA)
Spain (ES)
Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
